The effect of gadodiamide on cancer cell lines

Aim: Recent literature suggests that some human cancer cell lines possess a calcium cation receptor. Human myeloma cell lines have demonstrated stimulated cell proliferation by the gadolinium cation through this receptor, and osteosarcoma cell lines possess the same cation receptor. Although enhance...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental Oncology
Datum:2009
Hauptverfasser: Fujimoto, T., Finnegan, M.
Format: Artikel
Sprache:Englisch
Veröffentlicht: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2009
Schlagworte:
Online Zugang:https://nasplib.isofts.kiev.ua/handle/123456789/138133
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Zitieren:The effect of gadodiamide on cancer cell lines / T. Fujimoto, M. Finnegan // Experimental Oncology. — 2009. — Т. 31, № 3. — С. 185-187. — Бібліогр.: 13 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
_version_ 1862680158539874304
author Fujimoto, T.
Finnegan, M.
author_facet Fujimoto, T.
Finnegan, M.
citation_txt The effect of gadodiamide on cancer cell lines / T. Fujimoto, M. Finnegan // Experimental Oncology. — 2009. — Т. 31, № 3. — С. 185-187. — Бібліогр.: 13 назв. — англ.
collection DSpace DC
container_title Experimental Oncology
description Aim: Recent literature suggests that some human cancer cell lines possess a calcium cation receptor. Human myeloma cell lines have demonstrated stimulated cell proliferation by the gadolinium cation through this receptor, and osteosarcoma cell lines possess the same cation receptor. Although enhanced MRI is a very useful diagnostic tool for the treatment of sarcoma in the orthopedic area, incorporating the use of MRI contrast agents based on gadolinium raises the possibility of the stimulation of cancer cell growth. Methods: Human myeloma (RPMI 8226), osteosarcoma (Saos-2) and rat osteosarcoma (UMR-106) cell lines were exposed to various concentrations of common MRI contrast agent gadodiamide (Omniscan®) (5 μM, 50 μM, 500 μM, 5 mM, 50 mM) in a culture medium. The response of the cells was then assessed by measuring cell proliferation and DNA synthesis. Results: Treatment with 5 μM to 5 mM gadodiamide did not stimulate cell proliferation; only cells exposed to 50 mM gadodiamide showed suppressed proliferation rates. Conclusions: Since intravenously injected gadodiamide is diluted from 500 μM to 1 mM by patient blood flow at enhanced MRI examinations, the results of the present study suggest that gadodiamide has not effect on these types of cancer cells.
first_indexed 2025-12-07T15:46:09Z
format Article
fulltext
id nasplib_isofts_kiev_ua-123456789-138133
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
issn 1812-9269
language English
last_indexed 2025-12-07T15:46:09Z
publishDate 2009
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
record_format dspace
spelling Fujimoto, T.
Finnegan, M.
2018-06-18T09:33:05Z
2018-06-18T09:33:05Z
2009
The effect of gadodiamide on cancer cell lines / T. Fujimoto, M. Finnegan // Experimental Oncology. — 2009. — Т. 31, № 3. — С. 185-187. — Бібліогр.: 13 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/138133
Aim: Recent literature suggests that some human cancer cell lines possess a calcium cation receptor. Human myeloma cell lines have demonstrated stimulated cell proliferation by the gadolinium cation through this receptor, and osteosarcoma cell lines possess the same cation receptor. Although enhanced MRI is a very useful diagnostic tool for the treatment of sarcoma in the orthopedic area, incorporating the use of MRI contrast agents based on gadolinium raises the possibility of the stimulation of cancer cell growth. Methods: Human myeloma (RPMI 8226), osteosarcoma (Saos-2) and rat osteosarcoma (UMR-106) cell lines were exposed to various concentrations of common MRI contrast agent gadodiamide (Omniscan®) (5 μM, 50 μM, 500 μM, 5 mM, 50 mM) in a culture medium. The response of the cells was then assessed by measuring cell proliferation and DNA synthesis. Results: Treatment with 5 μM to 5 mM gadodiamide did not stimulate cell proliferation; only cells exposed to 50 mM gadodiamide showed suppressed proliferation rates. Conclusions: Since intravenously injected gadodiamide is diluted from 500 μM to 1 mM by patient blood flow at enhanced MRI examinations, the results of the present study suggest that gadodiamide has not effect on these types of cancer cells.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Short communications
The effect of gadodiamide on cancer cell lines
Article
published earlier
spellingShingle The effect of gadodiamide on cancer cell lines
Fujimoto, T.
Finnegan, M.
Short communications
title The effect of gadodiamide on cancer cell lines
title_full The effect of gadodiamide on cancer cell lines
title_fullStr The effect of gadodiamide on cancer cell lines
title_full_unstemmed The effect of gadodiamide on cancer cell lines
title_short The effect of gadodiamide on cancer cell lines
title_sort effect of gadodiamide on cancer cell lines
topic Short communications
topic_facet Short communications
url https://nasplib.isofts.kiev.ua/handle/123456789/138133
work_keys_str_mv AT fujimotot theeffectofgadodiamideoncancercelllines
AT finneganm theeffectofgadodiamideoncancercelllines
AT fujimotot effectofgadodiamideoncancercelllines
AT finneganm effectofgadodiamideoncancercelllines